Caplyta and Hallucination, visual - a phase IV clinical study of FDA data

Summary:

Hallucination, visual is reported as a side effect among people who take Caplyta (lumateperone tosylate), especially for people who are female, 20-29 old, have been taking the drug for < 1 month also take Zoloft, and have Bipolar ii disorder.

The phase IV clinical study analyzes which people have Hallucination, visual when taking Caplyta. It is created by eHealthMe based on reports of 3,083 people who have side effects when taking Caplyta from the FDA, and is updated regularly.

What is Caplyta?

Caplyta has active ingredients of lumateperone tosylate. eHealthMe is studying from 3,109 Caplyta users. Check the latest studies of Caplyta.

What is Hallucination, visual?

Hallucination, visual (seeing things that aren't there) is found to be associated with 1,059 drugs and 1,370 conditions by eHealthMe. Check the latest studies of Hallucination, visual.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

3,083 people reported to have side effects when taking Caplyta.
Among them, 16 people (0.52%) have Hallucination, visual.

Could Caplyta cause Hallucination, visual?

Among these 16 people:

How long have people been on Caplyta when they have Hallucination, visual? *

What is the gender of people who have Hallucination, visual when taking Caplyta? *

female: 68.75 %
male: 31.25 %

What is the age of people who have Hallucination, visual when taking Caplyta? *

What are other drugs people take besides Caplyta? *

What are other side effects people have besides Hallucination, visual? *

Hallucination, Auditory (perceiving sounds without auditory stimulus): 6 people, 37.50%
Psychotic Disorder: 6 people, 37.50%
Headache (pain in head): 5 people, 31.25%
Anger: 5 people, 31.25%
Tremor (trembling or shaking movements in one or more parts of your body): 4 people, 25.00%
Sedation: 3 people, 18.75%
Diarrhea: 3 people, 18.75%
Memory Loss: 3 people, 18.75%
Peripheral Swelling: 3 people, 18.75%
Screaming (a long loud piercing cry): 3 people, 18.75%

What are the existing conditions these people have? *

Bipolar Ii Disorder (characterized by at least one episode of hypomania and at least one episode of major depression): 7 people, 43.75%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 3 people, 18.75%
Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 3 people, 18.75%
Sleep Disorder: 2 people, 12.50%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 12.50%
High Blood Pressure: 2 people, 12.50%
Psychotic Disorder: 1 person, 6.25%
Post-Traumatic Stress Disorder: 1 person, 6.25%
Obsessive-Compulsive Disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;): 1 person, 6.25%
Bipolar Disorder (mood disorder): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Caplyta and have Hallucination, visual?

- Check whether Hallucination, visual is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Caplyta:

Caplyta (3,109 reports)

Browse all side effects of Caplyta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hallucination, visual:

Hallucination, visual (1,059 drugs)

Browse all the conditions that are associated with Hallucination, visual:

Hallucination, visual (1,370 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lumateperone tosylate (the active ingredients of Caplyta) and Caplyta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.